Dyne Therapeutics (DYN) Q3 2026 earnings review
Dyne's drug review stays on schedule, but costs rise 73%
Dyne, which develops drugs for rare inherited muscle diseases, spent heavily to get ready for its first launch. Operating costs rose 73% from a year ago, because the company built drug supply and hired launch staff. A July share sale raised $405 million to pay for that work. Chief executive John Cox plans a US launch of z-rostudirsen, a drug for a muscle-wasting disease in boys, if regulators approve it.
| Net loss | $193.6M $108.0M a year ago |
|---|---|
| Operating costs | +73% from a year ago |
| Cash and short-term investments | $1.134B $898.5M at the end of June |
| Funding horizon | Unchanged into the second quarter of 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged, because every date Dyne gave last quarter still holds. US regulators kept their January decision date for z-rostudirsen, and results for its second drug remain due in early 2027. One caution: the share sale did not extend the funding horizon, because Dyne had already counted that money in its previous report.
The question now is whether Dyne can earn money from sales before its cash runs low. If z-rostudirsen wins approval and sells well, sales start to offset the costs; if it does not, Dyne must raise more from shareholders or lenders. The January decision and the first months of sales will tell.
🐂 Bull Case
FDA Will Rule on First Drug January 21
Dyne's lead drug, z-rostudirsen, treats Duchenne muscular dystrophy (DMD), an inherited disease that wastes the muscles of boys. It targets the form of the disease linked to a gene section called exon 51, about 13% of patients. The US Food and Drug Administration (FDA) reviews the application on a faster track and set January 21, 2027 for its decision.
Dyne is building drug supply before that decision. Direct spending on z-rostudirsen nearly tripled from a year ago, to $66.9 million, and the release credits "increased manufacturing activity for z-rostudirsen". That drug now takes 41% of research costs, against 23% a year earlier.
This matters because z-rostudirsen would give Dyne its first sales, which could start soon after approval. But Dyne asked only for accelerated approval, which rests on a muscle protein called dystrophin rather than on proven gains in strength. FORZETTO, a larger trial, must later show that treated boys rise from the floor faster.
What to watch: the FDA decision on January 21, 2027. An approval would turn the supply Dyne built this year into its first product for sale.
Second Drug Showed Gains After One Year
Z-basivarsen, Dyne's second drug, treats myotonic dystrophy type 1 (DM1), an inherited muscle disease. In September the biotech showed one-year data from early patients in its ACHIEVE trial. Treated patients improved "versus placebo and versus a matched natural history cohort", a group of similar untreated patients, the company said.
The final ACHIEVE group of 71 patients finished enrolling in June, and Dyne plans to report their results in early 2027. But those results, not the early data, decide whether it can file for approval later that year.
What to watch: how fast patients open a clenched hand after six months in the ACHIEVE results, due in early 2027. A clear gain would keep the filing and a 2028 launch on schedule.
🐻 Bear Case
New Cash Did Not Extend Dyne's Funding
Chief executive John Cox said Dyne is "investing across multiple programs" as it works toward its first sales. With no revenue, the company pays for that work with money from investors and lenders. A July share sale brought in $404.9 million after fees, from 21 million new shares.
Yet the funding date did not move. Dyne still says its cash lasts into the second quarter of 2028, because its previous report had already counted the July money. By our math, the quarter's cash use came to about $171 million before the share sale money.
This cuts against the comfort of that date. By our math, the date allows about $175 million of spending a quarter, and Dyne already spends close to that. Its filing says manufacturing costs will "increase progressively each quarter", and that the biotech "will need substantial additional funding".
What to watch: cash used in the fourth quarter, reported early in 2027. A figure above $175 million would move the funding date earlier, unless sales from a January approval start first.
Dyne Funds Itself With More Shares and Debt
Dyne pays for its work by selling new shares and by borrowing, and both now cost its owners more. The average share count rose 28% from a year ago, to 182 million, after a series of share sales.
The net loss grew faster than the share count, so the loss per share widened to $1.06 from $0.76. Interest expense doubled, because the drug developer has drawn $200 million from its lender, Hercules Capital.
The loan also sets a sales test. Nine months after an approval, Dyne must reach a minimum level of drug sales while it owes over $100 million. Enough cash on hand lifts that test.
What to watch: whether Dyne draws more of its loan after an approval. More debt would add interest costs and keep the sales test in force.
Risks this quarter didn't answer
Several standing risks to Dyne's case got no new evidence in this quarter's release or filing. Each one needs a specific event or number before it can move the case either way.
- FDA view of the evidence: Dyne seeks accelerated approval based on dystrophin, a muscle protein; the January 21 decision settles it.
- Safety: earlier trials showed fevers with z-rostudirsen and liver enzyme rises with z-basivarsen; the approved label would show any limits.
- Price and payers: approved drugs of this type cost about $1 million a year per patient; Dyne has not set a price.
- Rival treatments: about half of exon 51 patients already take a disease-modifying drug; launch sales will show how many switch.
👓 Other Themes
Tariffs Have Not Raised Dyne's Costs So Far
Dyne buys drug ingredients and manufacturing from outside suppliers, so US tariffs could reach its costs. Its filing says the drug developer has not felt and does not expect "significant direct impact from these tariffs". Dyne still warns that trade policy could disrupt supply and delay trials or a launch.
Dyne Reclassifies $18.8 Million of Factory Equipment
Dyne changed its contract with a drug manufacturer, so it no longer counts $18.8 million of factory equipment as its own. The filing now treats the sum as a long-term asset that the maker will credit "towards future batch manufacturing fees". Property and equipment fell to $7.1 million as a result, and no cash changed hands.
Four Duchenne Drugs Move Toward Human Trials
Dyne showed early lab data for four drugs aimed at other forms of Duchenne, each linked to a different gene section. Cox said these programmes could "expand our reach to over one third of individuals living with Duchenne". The FDA also cleared a first human trial of DYNE-302 for facioscapulohumeral dystrophy (FSHD), another inherited muscle disease.
💲 Other KPIs
Research and development spending rose 66% from a year ago, to $161.7 million. Growth has sped up each quarter this year, after a small decline in the first quarter. Early-stage lab work on its FORCE technology, which carries drugs into muscle, explains part of it: platform and outside research reached $21.5 million.
Prepayments climbed to $41.6 million from $16.0 million at the end of 2025. These are sums Dyne paid ahead for services not yet delivered. The filing links the change to more trial and manufacturing work, and the build-up took $25.7 million of cash this year.
By our math, the biotech owes two contract manufacturers about $122.7 million more under capacity deals running to 2028. The larger agreement accounts for $69.4 million through September 2028. Ending either deal early would still cost fees for work done and materials bought.
🔮 Guidance
Unchanged. Dyne still says its cash lasts into the second quarter of 2028. That leaves about six full quarters of funding, down from seven in the previous report. The date excludes any drug sales and up to $125 million of extra loans tied to milestones.
Unchanged. US regulators still aim to rule on z-rostudirsen, Dyne's Duchenne drug, by January 21, 2027. The agency accepted the application in July and granted it priority review, a shorter review clock.
Unchanged. Dyne plans to start selling the drug in the US in the first quarter of 2027, if approval arrives on time. Launch hiring already shows in administrative costs.
Unchanged. Results from the final ACHIEVE group, testing z-basivarsen in myotonic dystrophy type 1, remain due in the first quarter of 2027. These data decide the filing for approval.
Unchanged. Dyne plans to apply for accelerated approval of z-basivarsen in the third quarter of 2027. Earlier this year the target named the early part of that quarter; since the previous report it names only the quarter.
Unchanged. The drug developer still targets a US launch in the first half of 2028, if the FDA grants a faster review. Earlier this year Dyne named a narrower target, the start of that half.
New. Dyne expects manufacturing to take 55–65% of its 2026 research spending. It plans for these costs to climb every quarter, because supply takes a long time to build. Trials take a further 10–20%, so most spending goes into drug supply rather than tests.
❓ Key Questions
What price will Dyne set for z-rostudirsen?
Approved drugs of this type cost about $1 million a year per patient, and Medicaid pays for over half of Duchenne treatment. The price decides how fast launch sales offset rising costs.
How much cash will Dyne use in 2027?
Costs rose every quarter this year, and the funding date ends close to the second launch. A spending plan for 2027 would show whether Dyne needs new money before z-basivarsen sales start.
How many patients are ready to start at launch?
About half of eligible exon 51 patients already take another drug. The number of centres and patients signed up before January would show how fast sales can start.
When will Dyne draw the next loan tranche?
Up to $125 million more depends on clinical and sales milestones. The funding date leaves these tranches out, so their timing changes both the cash and the interest bill.
When will FORZETTO show results on strength?
Accelerated approval rests on dystrophin levels. FORZETTO measures rising from the floor at week 73, so its timing decides how long any approval stays conditional.